CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Mesenchymal Stromal Cells infusionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug1450 Medical Mask Wiki 1.00
drug1545 N95 respirator Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 Safety and Feasibility of Allogenic Mesenchymal Stromal Cells in the Treatment of COVID-19

Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available. For severe cases, it was found that aberrant pathogenic T cells and inflammatory monocytes are rapidly activated and then producing a large number of cytokines and inducing an inflammatory storm. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate the safety and efficacy of intravenous infusion of mesenchymal stem cells in severe patients with COVID-19.

NCT04467047 COVID-19 Sars-CoV2 Biological: Mesenchymal Stromal Cells infusion

Primary Outcomes

Description: Assessment of Overall survival at 30 days post intervention

Measure: Overall survival

Time: 60 days

Secondary Outcomes

Description: To assess the anti-inflammatory effect of the proposed treatment with assessment of the levels of C-reactive protein (mg/dL)

Measure: Changes on inflammatory C-reactive protein

Time: 60 days

Description: days of the patients in hospital

Measure: Hospital stay

Time: 60 days

Description: Evaluation of functional respiratory changes: PaO2 / FiO2 ratio

Measure: Oxygenation index (PaO2/FiO2)

Time: 60 days

Description: Improvement in Liao's score (2020)

Measure: Improvement in Liao's score (2020)

Time: 60 days

Description: Computed tomography Chest assesment will be done to assess improvement in radiological findings of COVID-19

Measure: Radiological improvement

Time: 60 days

Description: PCR testing to check PCR negativity

Measure: Time of COVID19 PCR negativity

Time: 28 days


No related HPO nodes (Using clinical trials)